Translational Cancer Therapy

Norwegian Radium Hospital, Oslo University Hospital Logo TCT small

The Translational Cancer Therapy Group’ s project portfolio can be summarized in three main translational research themes; basing project execution on experimental models, clinical studies and state-of-the-art molecular methods: 1) Identification of prognostic and predictive biomarkers 2) Assessment of drug efficacy 3) The metastatic process – biology and therapy. At present, much effort is focused on molecular characterization of metastatic tissues from different locations (liver, lung, peritoneum, brain), the ultimate aim being to identify biomarkers of tumor metastasis that might be utilized therapeutically.

OUS Website for Professor Flatmark’s Group (External link)


Kjersti Flatmark, Professor, MD, PhD

Position: Group leader, Professor of Surgery, University of Oslo; Consultant Surgeon, Norwegian Radium Hospital, Oslo University Hospital.

Research interest: Translational studies focusing on identification of prognostic and predictive biomarkers and preclinical and early clinical trials studying drug efficacy and tolerability; biobanking; experimental models of primary and metastatic colorectal cancer; peritoneal surface malignancies; locally advanced and recurrent rectal cancer; molecular characterization of metastases from different metastatic locations.
Annette Torgunrud, PhD

Position: Researcher

Research interest: The main focus is an on-going project where the aim is to determine the presence of exfoliated tumour cells in peritoneal lavage samples from patients undergoing surgery for Local Advanced rectal Cancer and analyse associations between the presence of tumour cells and clinicopathological parameters and disease outcome. Additionally my interest is biobanking samples from patients with peritoneal surface malignancy to identify prognostic factors and biomarkers to optimize patient selection for treatment.
Yvonne Andersson, PhD

Position: Senior Scientist

Research interest: Preclinical and translational studies on peritoneal surface malignancies (PSM) and new therapy strategies of PSM; characterization in vitro and in vivo and conducting clinical Phase I trials; immunotoxins/targeted therapeutics; use of an immunotoxin for PSM as an attractive candidate for local therapy in the peritoneal cavity.
Karianne Giller Fleten

Position: Post-Doc

Main Activities: Investigation of the potential for new drugs and treatment strategies in experimental colorectal cancer liver metastasis models.
Eirik Høye

Position: PhD Student

Main Activities: MicroRNAs in hepatic metastasis disease from colorectal cancer
Vegar Johansen Dagenborg, MD

Position: PhD student

PhD project: Metastastic colorectal cancer. Liver metastasis from colorectal cancer. Hepatobiliary surgery. Surgery for metastatic cancer. Biomarkers in cancer. Molecular changes in cancer.
Christin Lund-Andersen, PhD

Position: Postdoc

Research interest: Multilevel characterization of peritoneal carcinomatosis from colorectal cancer. Focusing on bioinformatic analysis to find new biomarkers and therapeutic targets to improve treatment, as well as to increase our understanding of the metastatic phenotype. Background in molecular biology; Sivilingeniør (MSc) in Chemistry/Biotechnology and PhD regarding cell cycle regulation in cancer.
Ina Katrine Nitschke Pettersen, PhD

Position: Laboratory Engineer

Research Interests:Molecular biology and cell metabolism. Updating, processing and organise the biobank containing samples from patients with peritoneal surface malignancy.
Arne M. Solbakken

Position: MD/PhD Student
Franz Suurs, PhD

Position: Post-Doc

Research Interests:Targeted alpha therapy project in collaboration with Bayer.
Thale Dawn Patrick-Brown, MSc, MIET

Position: Research Coordinator

Research Interests: Epidemiology; neurophysiology; protein expression in epithelial tissue; coding and programming of websites (hello world!).




Aghayan DL, Kazaryan AM, Dagenborg VJ, Røsok BI, Fagerland MW, Waaler Bjørnelv GM, Kristiansen R, Flatmark K, Fretland ÅA, Edwin B. Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial. (2021). Ann Intern Med. 2021 Feb;174(2):175-182. doi: 10.7326/M20-4011. Epub 2020 Nov 17. PMID: 33197213

Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K. Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. (2021). Ann Surg Oncol. Jan;28(1):252-257. doi: 10.1245/s10434-020-08655-8. Epub 2020 Jun 2. PMID: 32488520

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K. ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. (2021). Eur J Surg Oncol. 2021 Jan;47(1):134-138. doi: 10.1016/j.ejso.2019.04.014. Epub 2019 Apr 22. PMID: 31036394


Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K. (2020). Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biol Ther, 21 (5), 432-440. DOI 10.1080/15384047.2020.1721252, PMID: 32098573

Flatmark K, Mohamed F. ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. (2020). Ann Surg Oncol. Dec;27(Suppl 3):771-772. doi: 10.1245/s10434-020-08691-4. Epub 2020 Jun 3. PMID: 32495284

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K. Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models. (2020). Transl Oncol. Aug;13(8):100793. doi: 10.1016/j.tranon.2020.100793. Epub 2020 May 21. PMID: 32447231

De Las Heras J, Diez I, Jimenez-Marin A, Cabrera A, Ramos-Usuga D, Diaz-Fernandez MV, Torices L, Nunes-Xavier CE, Pulido R, Arango-Lasprilla JC, Cortes JM. (2020). Brain Circuit Alterations and Cognitive Disability in Late-Onset Cobalamin D Disorder. J Clin Med, 9 (4). DOI 10.3390/jcm9040990, PubMed 32252256

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ. (2020). MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res, 48 (D1), D1172. DOI 10.1093/nar/gkz1016, PubMed 31642479

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ. (2020). MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res, 48 (D1), D132-D141. DOI 10.1093/nar/gkz885, PubMed 31598695

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø. (2019). Immune stimulatory effect of anti-EpCAM immunotoxin – improved overall survival of metastatic colorectal cancer patients. Acta Oncol, 59 (4), 404-409. DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. (2020). Corrigendum to “Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer” [Transl Oncol 12 (8) (2019) 1038-1044]. Transl Oncol, 13 (1), 122-124. DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K. (2020). Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. Acta Oncol. DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, Fodstad Ø, Andersson Y (2020). Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. Ann Diagn Pathol, 46, 151483 (in press). DOI 10.1016/j.anndiagpath.2020.151483, PubMed 32143173


Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH. (2019). High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer. BMC Cancer, 19 (1), 488. DOI 10.1186/s12885-019-5724-z, PubMed 31122213

Aghayan DL, Fretland ÅA, Kazaryan AM, Sahakyan MA, Dagenborg VJ, Bjørnbeth BA, Flatmark K, Kristiansen R, Edwin B. (2019). Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial. HPB (Oxford), 21 (11), 1485-1490. DOI 10.1016/j.hpb.2019.03.358, PubMed 30962136

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH. (2019). Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. Cancer Immunol Immunother, 69 (3), 355-364. DOI 10.1007/s00262-019-02458-x, PubMed 31893287

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29. PubMed PMID: 30273860; PubMed Central PMCID: PMC6170256.

Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, Song J, Li L, Dagenborg VJ, Fretland ÅA, Røsok B, De Rose AM, Ardito F, Edwin B, Panettieri E, Larocca LM, Yamashita S, Conrad C, Aloia TA, Poston GJ, Bjørnbeth BA, Vauthey JN (2019). RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases. Ann Surg, 269 (1), 120-126. DOI 10.1097/SLA.0000000000002319, PubMed 28549012

Calvete J, Larrinaga G, Errarte P, Martín AM, Dotor A, Esquinas C, Nunes-Xavier CE, Pulido R, López JI, Angulo JC. (2019). The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum Pathol, 91, 61-68. DOI 10.1016/j.humpath.2019.07.002, PubMed 31279874

Flem-Karlsen K, Fodstad Y, Nunes-Xavier CE. (2019). B7-H3 immune checkpoint protein in human cancer. Curr Med Chem (in press). DOI 10.2174/0929867326666190517115515, PubMed 31099317

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE. (2019). p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Sci Rep, 9 (1), 5839. DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. (2019).A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol, 12 (7), 951-958. DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Fretland ÅA, Dagenborg VJ, Waaler Bjørnelv GM, Aghayan DL, Kazaryan AM, Barkhatov L, Kristiansen R, Fagerland MW, Edwin B, Andersen MH. (2019). Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases. Br J Surg, 106 (10), 1372-1380. DOI 10.1002/bjs.11227, PubMed 31322735

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ. MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res. 2019 Oct 23. pii: gkz1016. doi: 10.1093/nar/gkz1016. [Epub ahead of print] PubMed PMID: 31642479.

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ. MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res. 2019 Oct 10. pii: gkz885. doi: 10.1093/nar/gkz885. [Epub ahead of print] PubMed PMID: 31598695.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K. (2019). ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. Eur J Surg Oncol (in press). DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394

Hansen EP, Fromm B, Andersen SD, Marcilla A, Andersen KL, Borup A, Williams AR, Jex AR, Gasser RB, Young ND, Hall RS, Stensballe A, Ovchinnikov V, Yan Y, Fredholm M, Thamsborg SM, Nejsum P. (2019). Exploration of extracellular vesicles from Ascaris suum provides evidence of parasite-host cross talk. J Extracell Vesicles, 8 (1), 1578116. DOI 10.1080/20013078.2019.1578116, PubMed 30815237

Hausken J, Fretland ÅA, Edwin B, Andersen MH, Dagenborg VJ, Bjørnelv GMW, Kristiansen R, Røysland K, Kvarstein G, Tønnessen TI. (2019). Intravenous Patient-controlled Analgesia Versus Thoracic Epidural Analgesia After Open Liver Surgery: A Prospective, Randomized, Controlled, Noninferiority Trial. Ann Surg, 270 (2), 193-199. DOI 10.1097/SLA.0000000000003209, PubMed 30676382

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003566. doi: 10.1101/mcs.a003566. Print 2019 Apr. PubMed PMID: 30862609; PubMed Central PMCID: PMC6549577.

Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S; List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol. 2019 Mar 23. pii: S0748-7983(19)30337-3. doi: 10.1016/j.ejso.2019.03.012. [Epub ahead of print] Review. PubMed PMID: 30954350.

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH. (2019). Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?. Clin Transl Radiat Oncol, 21, 5-10. DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Transl Oncol. 2019 Aug;12(8):1038-1044. doi: 10.1016/j.tranon.2019.04.014. Epub 2019 May 27. PubMed PMID: 31146167; PubMed Central PMCID: PMC6542769.

Mingo J, Luna S, Gaafar A, Nunes-Xavier CE, Torices L, Mosteiro L, Ruiz R, Guerra I, Llarena R, Angulo JC, López JI, Pulido R. (2019). Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology. NPJ Precis Oncol, 3, 11. DOI 10.1038/s41698-019-0083-4, PubMed 30993208

Nunes-Xavier CE, Angulo JC, Pulido R, López JI. (2019). A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Curr Urol Rep, 20 (1), 1. DOI 10.1007/s11934-019-0866-8, PubMed 30645700

Nunes-Xavier CE, Aurtenetxe O, Zaldumbide L, López-Almaraz R, Erramuzpe A, Cortés JM, López JI, Pulido R. (2019). Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma. Diagn Pathol, 14 (1), 134. DOI 10.1186/s13000-019-0919-9, PubMed 31837707

Nunes-Xavier CE, Zaldumbide L, Aurtenetxe O, López-Almaraz R, López JI, Pulido R. (2019). Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation. Int J Mol Sci, 20 (5). DOI 10.3390/ijms20051170, PubMed 30866462

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM. Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer Immunol Res. 2019 May;7(5):701-706. doi: 10.1158/2326-6066.CIR-18-0777. Epub 2019 Feb 25. PubMed PMID: 30804006.

Pulido R, Mingo J, Gaafar A, Nunes-Xavier CE, Luna S, Torices L, Angulo JC, López JI. (2019). Precise Immunodetection of PTEN Protein in Human Neoplasia. Cold Spring Harb Perspect Med, 9 (12). DOI 10.1101/cshperspect.a036293, PubMed 31501265

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM. (2019). Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer Immunol Res, 7 (5), 701-706. DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K. (2019). Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei. Clin Exp Metastasis, 36 (6), 511-518. DOI 10.1007/s10585-019-09991-0, PubMed 31541325


Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM. Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. J Control Release. 2019 Jan 10;293:183-192. doi: 10.1016/j.jconrel.2018.11.029. Epub 2018 Dec 4. PubMed PMID: 30529259.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26. PubMed PMID: 29695770; PubMed Central PMCID: PMC5959927.

Mikalsen SG, Mikalsen LTG, Sandvik JA, Aarnes EK, Fenne S, Flatmark K, Lyng H, Edin NFJ, Pettersen EO. Low dose-rate irradiation with [(3)H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model. Acta Oncol. 2018 Sep;57(9):1216-1224. doi: 10.1080/0284186X.2018.1457223. Epub 2018 Apr 9. PubMed PMID: 29630428.

Spasojevic M, Mariathasan AB, Goscinski M, Thorgersen EB, Solbakken AM, Gullestad HP, Ryder T, Flatmark K, Larsen SG. Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer. Ann Surg Oncol. 2018 May;25(5):1357-1365. doi: 10.1245/s10434-018-6363-3. Epub 2018 Mar 1. PubMed PMID: 29497909.


Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29. PubMed PMID: 29100358; PubMed Central PMCID: PMC5652752.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29. PubMed PMID: 29100312; PubMed Central PMCID: PMC5652706.

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K. MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer. Oncotarget. 2017 Jun 27;8(37):61800-61809. doi: 10.18632/oncotarget.18694. eCollection 2017 Sep 22. PubMed PMID: 28977905; PubMed Central PMCID: PMC5617465.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017. PubMed PMID: 28761742; PubMed Central PMCID: PMC5519811.

Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B. Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial. Ann Surg. 2018 Feb;267(2):199-207. doi: 10.1097/SLA.0000000000002353. PubMed PMID: 28657937.

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE. Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells. Pigment Cell Melanoma Res. 2017 Sep;30(5):467-476. doi: 10.1111/pcmr.12599. Epub 2017 Jul 4. PubMed PMID: 28513992.

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR. Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17. PubMed PMID: 28464745.

Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I. Pathway-based classification of breast cancer subtypes. Front Biosci (Landmark Ed). 2017 Jun 1;22:1697-1712. PubMed PMID: 28410140.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K. Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial. Ann Surg Oncol. 2017 Jul;24(7):1916-1922. doi: 10.1245/s10434-017-5814-6. Epub 2017 Feb 21. PubMed PMID: 28224367.

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K. Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. Clin Exp Metastasis. 2017 Jan;34(1):51-62. doi: 10.1007/s10585-016-9829-3. Epub 2016 Nov 3. PubMed PMID: 27812769.

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K. Expression and clinical significance of Wee1 in colorectal cancer. Tumour Biol. 2016 Sep;37(9):12133-12140. Epub 2016 May 24. PubMed PMID: 27220319.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Br J Cancer. 2016 Oct 11;115(8):929-939. doi: 10.1038/bjc.2016.278. Epub 2016 Sep 6. PubMed PMID: 27599042; PubMed Central PMCID: PMC5061908.

Flatmark K, Høye E, Fromm B. microRNAs as cancer biomarkers. Scand J Clin Lab Invest Suppl. 2016;245:S80-3. doi: 10.1080/00365513.2016.1210330. Epub 2016 Aug 9. PubMed PMID: 27542003.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28. PubMed PMID: 27488871; PubMed Central PMCID:


Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH. Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening. BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x. PubMed PMID: 27461255; PubMed Central PMCID: PMC4962367.

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Med. 2016 Aug;5(8):1840-9. doi:
10.1002/cam4.766. Epub 2016 Jun 8. PubMed PMID: 27273130; PubMed Central PMCID: PMC4971912.

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016 Aug;114(2):222-7. doi: 10.1002/jso.24290. Epub 2016 May 12. PubMed PMID: 27173150.

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995. PubMed PMID: 27145458; PubMed Central PMCID: PMC5085198.

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer – Targeting the tumor for radiation sensitivity? Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8. PubMed PMID: 26968754.

Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K. Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report. World J Surg Oncol. 2016 Mar 3;14:63. doi: 10.1186/s12957-016-0818-4. PubMed PMID: 26940557; PubMed
Central PMCID: PMC4778273.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T. High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17. PubMed PMID: 26705680.


Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ. A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome. Annu Rev Genet. 2015;49:213-42. doi: 10.1146/annurev-genet-120213-092023. Epub 2015 Oct 14. Review. PubMed PMID: 26473382; PubMed Central PMCID: PMC4743252.

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM. Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. Clin Exp Metastasis. 2015 Dec;32(8):755-67. doi: 10.1007/s10585-015-9742-1. Epub 2015 Sep 9. PubMed
PMID: 26349943.

Hektoen HH, Ree AH, Redalen KR, Flatmark K. Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells. J Enzyme Inhib Med Chem. 2016 Oct;31(5):779-86. doi: 10.3109/14756366.2015.1069286. Epub 2015 Aug 5. PubMed PMID: 26244271.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH. Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer. BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6. PubMed PMID: 26205955; PubMed Central PMCID: PMC4513373.

Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B. Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial. Trials. 2015 Mar 4;16:73. doi: 10.1186/s13063-015-0577-5. PubMed PMID: 25872027; PubMed Central PMCID: PMC4358911.

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR. Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies. Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12. PubMed PMID: 25624177.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E. Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks. Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Review. PubMed PMID: 25501337;
PubMed Central PMCID: PMC4284741.

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K. High expression of the cysteine proteinase legumain in colorectal cancer – implications for therapeutic targeting. Eur J Cancer. 2015 Jan;51(1):9-17. doi: 10.1016/j.ejca.2014.10.020. Epub 2014 Nov 11. PubMed PMID: 25466510.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review. PubMed PMID: 25347767.


Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø. B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer. 2014 Aug 20;14:602. doi: 10.1186/1471-2407-14-602. PubMed PMID: 25139714; PubMed Central PMCID: PMC4148536.

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K. Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy. PLoS One. 2014 Feb 25;9(2):e89750. doi: 10.1371/journal.pone.0089750. eCollection 2014. PubMed PMID: 24587009; PubMed Central PMCID: PMC3934935.

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y. The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells. J Ovarian Res. 2014 Feb 15;7:23. doi: 10.1186/1757-2215-7-23. PubMed PMID: 24528603; PubMed Central PMCID: PMC3931919.

2013 and Earlier

Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K. Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis. J Surg Oncol. 2014 May;109(6):521-6. doi: 10.1002/jso.23527. Epub 2013 Dec 17. PubMed PMID: 24347444.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10. PubMed PMID: 24035332.

Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer. 2013 Dec;12(4):261-6. doi: 10.1016/j.clcc.2013.06.003. Epub 2013 Sep 5. PubMed PMID: 24012455.

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K. Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer. PLoS One. 2013 Jun 18;8(6):e66165. doi: 10.1371/journal.pone.0066165. Print 2013. PubMed PMID: 23824282; PubMed Central PMCID: PMC3688869.

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer. 2013 Sep 15;133(6):1497-506. doi: 10.1002/ijc.28158. Epub 2013 Apr 17. PubMed PMID: 23494569.

Friedman R, Boye K, Flatmark K. Molecular modelling and simulations in cancer research. Biochim Biophys Acta. 2013 Aug;1836(1):1-14. doi: 10.1016/j.bbcan.2013.02.001. Epub 2013 Feb 14. Review. PubMed PMID: 23416097.

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM. Nuclear legumain activity in colorectal cancer. PLoS One. 2013;8(1):e52980. doi: 10.1371/journal.pone.0052980. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/05c95441-890f-4707-a1bc-c4d386561191. PubMed PMID: 23326369; PubMed Central PMCID: PMC3542341.

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K. Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PLoS One. 2012;7(11):e50806. doi: 10.1371/journal.pone.0050806. Epub 2012 Nov 30. PubMed PMID: 23226389; PubMed Central PMCID: PMC3511283.

Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012 Nov 2;12:505. doi: 10.1186/1471-2407-12-505. PubMed PMID: 23121918; PubMed Central PMCID: PMC3519622.

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol. 2012 Sep 27;7:165. doi: 10.1186/1748-717X-7-165. PubMed PMID: 23017053; PubMed Central
PMCID: PMC3488009.

Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer. 2012 Dec 1;131(11):2528-36. doi: 10.1002/ijc.27566. Epub 2012 Apr 24. PubMed PMID: 22473715.

Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma. Virchows Arch. 2012 Feb;460(2):193-202. doi: 10.1007/s00428-011-1191-x. Epub 2012 Jan 17. PubMed PMID: 22249560.

Schee K, Flatmark K, Holm R, Boye K, Paus E. Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients. Tumour Biol. 2012 Feb;33(1):73-83. doi: 10.1007/s13277-011-0247-5. Epub 2011 Oct 18. Erratum in: Tumour Biol. 2012 Aug;33(4):1263-4. PubMed PMID: 22006279.

Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH. Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis. 2011 Dec;14(4):481-9. doi: 10.1007/s10456-011-9231-3. Epub 2011 Aug 11. PubMed PMID: 21833622; PubMed Central PMCID: PMC3214264.

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol. 2011 Apr 8;6:33. doi: 10.1186/1748-717X-6-33. PubMed PMID: 21473790; PubMed Central PMCID: PMC3086833.

Schee K, Fodstad Ø, Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol. 2010 Oct;177(4):1592-9. doi: 10.2353/ajpath.2010.100024. Epub 2010 Sep 9. Review. PubMed PMID: 20829435; PubMed Central PMCID: PMC2947254.

Sørensen O, Andersen A, Olsen H, Alexandr K, Ekstrøm PO, Giercksky KE, Flatmark K. Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C – an experimental study. BMC Cancer. 2010 Sep 1;10:469. doi: 10.1186/1471-2407-10-469. PubMed PMID: 20809961; PubMed Central PMCID: PMC2940807.

Flatmark K, Ree AH. Radiosensitizing drugs: lessons to be learned from the oxaliplatin story. J Clin Oncol. 2010 Oct 10;28(29):e577-8; author reply e581-3. doi: 10.1200/JCO.2010.30.0921. Epub 2010 Aug 23. PubMed PMID: 20733124.

Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K. Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer. 2010 Nov;46(16):2919-25. doi: 10.1016/j.ejca.2010.07.013. Epub 2010 Aug 16. PubMed PMID: 20719498.

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH. Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):555-62. doi: 10.1016/j.ijrobp.2010.04.036. Epub 2010 Aug 2. PubMed PMID: 20675069.

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T. TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins. Tumour Biol. 2011 Feb;32(1):1-12. doi: 10.1007/s13277-010-0073-1. Epub 2010 Jul 24. PubMed PMID: 20652782.

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010 May;11(5):459-64. doi:
10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6. PubMed PMID: 20378407.

Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W. Exploring the peritoneal surface malignancy phenotype–a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol. 2010 Aug;41(8):1109-19. doi: 10.1016/j.humpath.2009.12.013. Epub 2010 Mar 24. PubMed PMID: 20338618.

Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K. Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma. Amino Acids. 2011 Oct;41(4):875-84. doi: 10.1007/s00726-010-0514-6. Epub 2010 Feb 27. PubMed PMID: 20191297.

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E. MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiother Oncol. 2009 Nov;93(2):279-84. doi: 10.1016/j.radonc.2009.08.046. Epub 2009 Oct 1. PubMed PMID: 19800704.

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068. PubMed PMID: 19427556.

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B. Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol. 2009;30(1):15-25. doi: 10.1159/000199447. Epub 2009 Feb 5. PubMed PMID: 19194111.

Ree AH, Folkvord S, Flatmark K. HDAC2 deficiency and histone acetylation. Nat Genet. 2008 Jul;40(7):812-3; author reply 813. doi: 10.1038/ng0708-812. PubMed PMID: 18583969.

Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM. The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications. BMC Cancer. 2008 Jun 13;8:172. doi: 10.1186/1471-2407-8-172. PubMed PMID: 18554396; PubMed Central PMCID: PMC2443394.

Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF. Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy. Mol Cancer. 2008 Apr 25;7:33. doi: 10.1186/1476-4598-7-33. PubMed PMID: 18439252; PubMed Central PMCID: PMC2377266.

Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O. Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer. 2008 Aug;61(2):170-6. doi: 10.1016/j.lungcan.2007.12.018. Epub 2008 Feb 7. PubMed PMID: 18261824.

Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol. 2008 Mar;86(3):428-34. Epub 2007 Nov 19. PubMed PMID: 18006097.

Flatmark K, Reed W, Halvorsen T, Sørensen O, Wiig JN, Larsen SG, Fodstad Ø, Giercksky KE. Pseudomyxoma peritonei–two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. BMC Cancer. 2007 Jun 30;7:116. PubMed PMID: 17603904; PubMed Central PMCID: PMC1920528.

Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR. Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice. Neoplasia. 2007 May;9(5):392-400. PubMed PMID: 17534444; PubMed Central PMCID: PMC1877980.

Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol. 2006 Aug 3;1:25. PubMed PMID: 16887021; PubMed Central PMCID: PMC1553456.

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y. DNA damage responses in cell cycle G2 phase and mitosis–tracking and targeting. Anticancer Res. 2006 May-Jun;26(3A):1909-16. PubMed PMID: 16827124.

Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 2005 Aug;127(2):151-6. Epub 2005 Apr 14. PubMed PMID: 16083752.

Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer. 2004 Jul;40(10):1593-8. PubMed PMID: 15196545.

Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E. Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol. 2004 Jan-Apr;25(1-2):31-40. PubMed PMID: 15192310.

Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, Maelandsmo GM. Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol. 2003 Aug;200(5):589-95. PubMed PMID: 12898594.

Bjørnland K, Flatmark K, Mala T, Mathisen O, Bakka A, Aasen AO, Bergan A, Søreide O, Fodstad O. Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer. J Surg Oncol. 2003 Apr;82(4):224-7. PubMed PMID: 12672004.

Flatmark K, Bjørnland K, Johannessen HO, Hegstad E, Rosales R, Hårklau L, Solhaug JH, Faye RS, Søreide O, Fodstad Ø; Study Group for Micrometastases in BM in Colorectal Cancer. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res. 2002 Feb;8(2):444-9. PubMed PMID: 11839662.

Leave a Reply